MA29849B1 - Composes exercant une activite au niveau du recepteur m1 et leurs utilisations en medecine - Google Patents
Composes exercant une activite au niveau du recepteur m1 et leurs utilisations en medecineInfo
- Publication number
- MA29849B1 MA29849B1 MA30812A MA30812A MA29849B1 MA 29849 B1 MA29849 B1 MA 29849B1 MA 30812 A MA30812 A MA 30812A MA 30812 A MA30812 A MA 30812A MA 29849 B1 MA29849 B1 MA 29849B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- medicine
- alkyl
- activity
- substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000000694 effects Effects 0.000 title abstract 3
- 125000001153 fluoro group Chemical group F* 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 102000017927 CHRM1 Human genes 0.000 abstract 2
- 101150073075 Chrm1 gene Proteins 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0519950.0A GB0519950D0 (en) | 2005-09-30 | 2005-09-30 | Compounds |
| GB0602040A GB0602040D0 (en) | 2006-02-01 | 2006-02-01 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29849B1 true MA29849B1 (fr) | 2008-10-03 |
Family
ID=37598231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30812A MA29849B1 (fr) | 2005-09-30 | 2008-04-04 | Composes exercant une activite au niveau du recepteur m1 et leurs utilisations en medecine |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8283364B2 (https=) |
| EP (1) | EP1943230B1 (https=) |
| JP (1) | JP5209480B2 (https=) |
| KR (2) | KR101374458B1 (https=) |
| CN (1) | CN101321736B (https=) |
| AR (1) | AR056103A1 (https=) |
| AT (1) | ATE492537T1 (https=) |
| AU (1) | AU2006296369B2 (https=) |
| BR (1) | BRPI0616609A2 (https=) |
| CA (1) | CA2624504C (https=) |
| CR (1) | CR9904A (https=) |
| DE (1) | DE602006019119D1 (https=) |
| EA (1) | EA016286B1 (https=) |
| IL (1) | IL190219A (https=) |
| JO (1) | JO2634B1 (https=) |
| MA (1) | MA29849B1 (https=) |
| MY (1) | MY148504A (https=) |
| NO (1) | NO20081945L (https=) |
| NZ (1) | NZ566508A (https=) |
| PE (1) | PE20070490A1 (https=) |
| TW (1) | TWI389905B (https=) |
| UA (1) | UA101299C2 (https=) |
| WO (1) | WO2007036715A2 (https=) |
| ZA (1) | ZA200802167B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0616609A2 (pt) | 2005-09-30 | 2011-06-28 | Glaxo Group Ltd | compostos que têm atividade no receptor m1, composição farmacêutica contendo tais compostos, processo para preparação dos mesmos, bem como seus usos em medicina |
| WO2007036711A1 (en) | 2005-09-30 | 2007-04-05 | Glaxo Group Limited | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR |
| EP1960389B1 (en) * | 2005-09-30 | 2012-08-15 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
| US7766829B2 (en) * | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
| GB0605785D0 (en) * | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
| GB0706164D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706174D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706170D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706165D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0718415D0 (en) * | 2007-09-20 | 2007-10-31 | Glaxo Group Ltd | Compounds |
| WO2009124882A1 (en) * | 2008-04-09 | 2009-10-15 | H. Lundbeck A/S | Novel piperidinyl-1,3-dihydro-benzoimidazol-2-ones as m1 agonists |
| GB0817982D0 (en) | 2008-10-01 | 2008-11-05 | Glaxo Group Ltd | Compounds |
| US20170333407A1 (en) * | 2014-11-03 | 2017-11-23 | William Beaumont Hospital | Method for treating underactive bladder syndrome |
| RS61688B1 (sr) | 2015-04-29 | 2021-05-31 | Janssen Pharmaceutica Nv | Azabenzimidazoli i njihiova upotreba kao modulatori ampa receptora |
| US10604484B2 (en) * | 2015-04-29 | 2020-03-31 | Janssen Pharmaceutica Nv | Indolone compounds and their use as AMPA receptor modulators |
| US20180250270A1 (en) | 2015-09-11 | 2018-09-06 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
| CN107673994A (zh) * | 2017-04-27 | 2018-02-09 | 联化科技股份有限公司 | 一种芳基甲烷类化合物的制备方法 |
| CN107739342B (zh) * | 2017-11-29 | 2020-01-10 | 华南理工大学 | 一种一步合成5-二芳氨基苯并咪唑酮衍生物的方法 |
| CN117049938B (zh) * | 2023-06-20 | 2024-06-14 | 山东轩德医药科技有限公司 | 一种6-溴-2,3-二氟甲苯的制备方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3161645A (en) | 1962-12-18 | 1964-12-15 | Res Lab Dr C Janssen N V | 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds |
| US3989707A (en) * | 1974-06-21 | 1976-11-02 | Janssen Pharmaceutica N.V. | Benzimidazolinone derivatives |
| US4292321A (en) | 1979-05-24 | 1981-09-29 | Warner-Lambert Company | 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof |
| DE3124366A1 (de) | 1981-06-20 | 1982-12-30 | Hoechst Ag, 6000 Frankfurt | N-oxacyclyl-alkylpiperidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung |
| DE4040300A1 (de) | 1990-12-17 | 1992-07-02 | Leifeld Gmbh & Co | Drueckmaschine mit wenigstens einem rollenhalter |
| JP3916093B2 (ja) * | 1993-09-17 | 2007-05-16 | 杏林製薬株式会社 | 光学活性イミダゾリジノン誘導体とその製造方法 |
| US5574044A (en) | 1994-10-27 | 1996-11-12 | Merck & Co., Inc. | Muscarine antagonists |
| JP2002515008A (ja) * | 1994-10-27 | 2002-05-21 | メルク エンド カンパニー インコーポレーテッド | ムスカリン・アンタゴニスト |
| US5691323A (en) * | 1995-05-12 | 1997-11-25 | Merck & Co., Inc. | Muscarine antagonists |
| WO1997016186A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Muscarine agonists |
| US5718912A (en) | 1996-10-28 | 1998-02-17 | Merck & Co., Inc. | Muscarine agonists |
| US5977134A (en) | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6465484B1 (en) | 1997-09-26 | 2002-10-15 | Merck & Co., Inc. | Angiogenesis inhibitors |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| AU2307999A (en) * | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| ATE275141T1 (de) | 1999-10-13 | 2004-09-15 | Banyu Pharma Co Ltd | Substituierte imidazolin-derivate |
| SE9904652D0 (sv) | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
| US20020019395A1 (en) | 2000-02-01 | 2002-02-14 | Bing-Yan Zhu | Indalone and benzimidazolone inhibitors of factor Xa |
| US6872733B2 (en) | 2001-04-18 | 2005-03-29 | Euro-Celtique S.A. | Benzimidazolone compounds |
| JPWO2002085890A1 (ja) | 2001-04-20 | 2004-08-12 | 萬有製薬株式会社 | ベンズイミダゾロン誘導体 |
| ATE516030T1 (de) | 2001-10-02 | 2011-07-15 | Acadia Pharm Inc | Benzimidazolidinon-derivate als muscarinische mittel |
| US6951849B2 (en) | 2001-10-02 | 2005-10-04 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| WO2004089942A2 (en) * | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| WO2003037890A2 (en) | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Piperidines |
| JP4056977B2 (ja) | 2002-03-29 | 2008-03-05 | 田辺三菱製薬株式会社 | 睡眠障害治療薬 |
| JP2005532361A (ja) | 2002-06-17 | 2005-10-27 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症の治療用の眼科用組成物 |
| BR0317230A (pt) | 2002-12-13 | 2005-10-25 | Smithkline Beecham Corp | Composto, composição, métodos de antagonizar uma atividade do receptor de quimiocina ccr-5, e de tratar uma infecção viral em um paciente, e, uso de um composto |
| JP2005102133A (ja) | 2003-04-28 | 2005-04-14 | Ricoh Co Ltd | 画像形成装置及び宛先情報参照方法 |
| WO2005009996A1 (en) | 2003-07-23 | 2005-02-03 | Wyeth | Sulfonyldihydro- benzimidazolone compounds as 5-hydroxytryptamine-6 ligands |
| KR100738784B1 (ko) | 2003-09-03 | 2007-07-12 | 화이자 인코포레이티드 | 5-ｈｔ4 수용체 효능 활성을 갖는 벤즈이미다졸론 |
| MX2007005290A (es) | 2004-11-02 | 2007-07-09 | Pfizer | Derivados de sulfonilbencimidazol. |
| US7300947B2 (en) | 2005-07-13 | 2007-11-27 | Banyu Pharmaceutical Co., Ltd. | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
| WO2007036711A1 (en) | 2005-09-30 | 2007-04-05 | Glaxo Group Limited | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR |
| EP1960389B1 (en) | 2005-09-30 | 2012-08-15 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
| BRPI0616609A2 (pt) | 2005-09-30 | 2011-06-28 | Glaxo Group Ltd | compostos que têm atividade no receptor m1, composição farmacêutica contendo tais compostos, processo para preparação dos mesmos, bem como seus usos em medicina |
| WO2008029377A2 (en) | 2006-09-08 | 2008-03-13 | The Gillette Company | Toothbrush with multiple bristle states |
| GB0706190D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706170D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706187D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706168D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706188D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706189D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706173D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706164D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706165D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706174D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706167D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
-
2006
- 2006-09-27 BR BRPI0616609-1A patent/BRPI0616609A2/pt not_active IP Right Cessation
- 2006-09-27 AU AU2006296369A patent/AU2006296369B2/en not_active Ceased
- 2006-09-27 KR KR1020087007797A patent/KR101374458B1/ko not_active Expired - Fee Related
- 2006-09-27 JP JP2008532866A patent/JP5209480B2/ja not_active Expired - Fee Related
- 2006-09-27 UA UAA200803937A patent/UA101299C2/uk unknown
- 2006-09-27 DE DE602006019119T patent/DE602006019119D1/de active Active
- 2006-09-27 MY MYPI20080901A patent/MY148504A/en unknown
- 2006-09-27 CN CN2006800451692A patent/CN101321736B/zh not_active Expired - Fee Related
- 2006-09-27 WO PCT/GB2006/003590 patent/WO2007036715A2/en not_active Ceased
- 2006-09-27 EA EA200801001A patent/EA016286B1/ru not_active IP Right Cessation
- 2006-09-27 NZ NZ566508A patent/NZ566508A/en not_active IP Right Cessation
- 2006-09-27 US US12/088,465 patent/US8283364B2/en not_active Expired - Fee Related
- 2006-09-27 KR KR1020137020049A patent/KR20130091791A/ko not_active Ceased
- 2006-09-27 EP EP06794584A patent/EP1943230B1/en active Active
- 2006-09-27 AT AT06794584T patent/ATE492537T1/de not_active IP Right Cessation
- 2006-09-27 CA CA2624504A patent/CA2624504C/en not_active Expired - Fee Related
- 2006-09-28 AR ARP060104268A patent/AR056103A1/es unknown
- 2006-09-28 PE PE2006001183A patent/PE20070490A1/es not_active Application Discontinuation
- 2006-09-28 TW TW095135887A patent/TWI389905B/zh not_active IP Right Cessation
- 2006-09-28 JO JO2006342A patent/JO2634B1/en active
-
2007
- 2007-09-10 US US11/852,455 patent/US8481566B2/en not_active Expired - Fee Related
-
2008
- 2008-03-17 IL IL190219A patent/IL190219A/en not_active IP Right Cessation
- 2008-04-04 MA MA30812A patent/MA29849B1/fr unknown
- 2008-04-18 CR CR9904A patent/CR9904A/es unknown
- 2008-04-23 NO NO20081945A patent/NO20081945L/no not_active Application Discontinuation
-
2009
- 2009-03-07 ZA ZA200802167A patent/ZA200802167B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29849B1 (fr) | Composes exercant une activite au niveau du recepteur m1 et leurs utilisations en medecine | |
| CA2662848C (fr) | Derives de 2-aryl-6-phenyl-imidazo[1,2-.alpha.]pyridines, leur preparation et leur application en therapeutique | |
| MA30324B1 (fr) | Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine. | |
| RU2332212C2 (ru) | Аминоспирт | |
| MA27390A1 (fr) | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique | |
| MA28422B1 (fr) | Derives de n- (1,5-diphenyl-1h-pyrazol-3-yl) sulfonamide avec une affinite pour les recepteurs cb1 | |
| CA2481461A1 (en) | Derivatives of n-[phenyl(piperidin-2-yl) methyl] benzamide, the preparation method thereof and application of same in therapeutics | |
| MA26989A1 (fr) | Derives de pyridine inhibiteurs de metalloproteinases de matrice | |
| TNSN06358A1 (fr) | Methyl-aryl-ou-heteroaryl-amides substitues | |
| MA31865B1 (fr) | Dérivés isoxazolo-pyridine | |
| TNSN07253A1 (fr) | Derives de n- (heteroaryl) -1h-indole-2-carboxamides et leur utilisation comme ligands du recepteur vanilloide trpv1 | |
| MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
| MA27573A1 (fr) | Sinomenine et derives de sinomenine, synthese et utilisation. | |
| MA34551B1 (fr) | Agent de lutte contre des organismes nuisibles | |
| MA27448A1 (fr) | Derives de pyridine modulateurs du recepteur cb2 | |
| TNSN07178A1 (fr) | N-sulfonylaminobenzyl-2-phenoxy-acetamides substitues | |
| MA33893B1 (fr) | Derives de diphenyl-pyrazolopyridines,leur preparation et leur appalication en therapeutique | |
| MA30014B1 (fr) | Derives spirocycliques | |
| FR2856684A1 (fr) | Derives de diphenylpyridine, leur preparation et leur application en therapeutique | |
| TN2011000550A1 (fr) | Derives de cyclopenta[c] pyrrolyla lkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique | |
| MA31674B1 (fr) | Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique | |
| MA29942B1 (fr) | Nouveaux derives d'hydroxy-acides gras insatures et leur utilisation dermocosmetologique | |
| FR2870541A1 (fr) | Derives de pyrimidines antigonistes du recepteur de la vitronectine | |
| TNSN05224A1 (fr) | Derives azabicycliques a substituants pyridyloxymethyle et benzisoxazole | |
| MA29559B1 (fr) | Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique |